GGrantIndex
Sort

48,018 grants matching immunotherapy

Tailoring AAV Vectors for Glioma Immunotherapy

$362,588
Ou Cao · University Of Florida · R01 · FY2010 · AI

Lung Cancer Vaccine

$362,579
Nasser Khaled Altorki · Weill Medical Coll Of Cornell Univ · U54 · FY2022 · CA

A novel T-cell subset able to kill relapsed cancers

$362,569
Qing Yi · Cleveland Clinic Lerner Com-Cwru · R01 · FY2016 · CA

The Germ Cell Gene TDRD1 As A Novel Prostate Cancer Biomarker

$362,569
Bin He · Baylor College Of Medicine · R01 · FY2017 · CA

Immunotherapy of human bladder cancer

$362,569
Lawrence Fong · University Of California, San Francisco · R01 · FY2017 · CA

Immunotherapy of human bladder cancer

$362,569
Lawrence Fong · University Of California, San Francisco · R01 · FY2015 · CA

A novel T-cell subset able to kill relapsed cancers

$362,569
Qing Yi · Cleveland Clinic Lerner Com-Cwru · R01 · FY2017 · CA

Immunotherapy of human bladder cancer

$362,569
Lawrence Fong · University Of California, San Francisco · R01 · FY2016 · CA

Immunotherapy of human bladder cancer

$362,569
Lawrence Fong · University Of California, San Francisco · R01 · FY2018 · CA

beta-Amyloid Antibodies with Specific Proteolytic Activity

$362,558
Sudhir Paul · University Of Texas Hlth Sci Ctr Houston · R01 · FY2008 · AG

Mechanisms of HSK amelioration

$362,500
Patrick M Stuart · Saint Louis University · R01 · FY2011 · EY

Myeloid-Derived Regulatory Cells in Asthma

$362,490
Jessy Satyadas Deshane · University Of Alabama At Birmingham · R01 · FY2017 · HL

Myeloid-Derived Regulatory Cells in Asthma

$362,490
Jessy Satyadas Deshane · University Of Alabama At Birmingham · R01 · FY2018 · HL

Myeloid-Derived Regulatory Cells in Asthma

$362,490
Jessy Satyadas Deshane · University Of Alabama At Birmingham · R01 · FY2016 · HL

Myeloid-Derived Regulatory Cells in Asthma

$362,490
Jessy Satyadas Deshane · University Of Alabama At Birmingham · R01 · FY2020 · HL

Myeloid-Derived Regulatory Cells in Asthma

$362,490
Jessy Satyadas Deshane · University Of Alabama At Birmingham · R01 · FY2019 · HL

HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C

$362,472
Neal Rosen · Sloan-Kettering Inst Can Research · P50 · FY2009 · CA

Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment

$362,472
Ling Gao · Southern California Inst For Res/Educ · R01 · FY2024 · CA

ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas

$362,434
David M. Ashley · Duke University · R01 · FY2024 · CA

Directing Function at the Natural Killer Cell Secretory Immunological Synapse

$362,428
Jordan Scott Orange · Columbia University Health Sciences · R01 · FY2018 · AI

Project 1: Siglec15 as a new target for lung cancer immunotherapy

$362,378
Lieping Chen · Yale University · P50 · FY2021 · CA

Targeted Nanomedicines with Synergistic Chemotherapeutics to Enhance Immunotherapy of Metastatic Colorectal Cancer

$362,362
Wenbin Lin · University Of Chicago · R01 · FY2022 · CA

A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.

$362,340
David E Fisher · Massachusetts General Hospital · R01 · FY2019 · CA

Project 1: Employing CD11b-Agonists to Render PDAC Responsive to Immunotherapy

$362,331
David G Denardo · Washington University · P50 · FY2024 · CA

Regulation of T Cell Activity During Chronic Infections

$362,324
Allan J Zajac · University Of Alabama At Birmingham · R56 · FY2014 · AI